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Abstract 
Cervical cancer (CC) is associated with alterations in immune system balance, 
which is primarily due to a shift from Th1 to Th2 and the unbalance of Th17/Treg 
cells. Using in silico DNA copy number analysis, we have demonstrated that 
~20% of CC samples exhibit gain of 8q22.3 and 19q13.31; the regions of the 
genome that encodes the KLF10 and PSG genes, respectively. Gene expression 
studies demonstrated that there were no alterations in KLF10 mRNA expression, 
whilst the PSG2 and -5 genes were up-regulated by 1.76 and 3.97-fold 
respectively in CC compared to normal tissue controls. siRNA and ChIP 
experiments in SiHa cells have demonstrated that KLF10 participates in immune 
response through regulation of IL6, IL25 and PSG2 and PSG5 genes. Using 
cervical tissues from KLF10-/- mice, we have identified down-regulation of 
PSG17, -21 and -23 and IL11. These results suggest that KLF10 may regulate 
immune system response genes in cervical cancer among other functions. 
KLF10 and PSG copy number variations and alterations in mRNA expression 
levels could represent novel molecular markers in CC.  
 
 
 
 
Keywords: Krüppel-Like Factor 10, Pregnancy-Specific Beta-1 Glycoproteins, 
Immune system Response, Cervical Cancer. 
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Introduction 
Cervical cancer (CC) is currently the second most common cancer among the 
female population1. As is the case with many other cancer types, host immune 
system evasion, involving the failure of the immune system to resist or eradicate 
formation and progression of incipient neoplastic cells, late-stage tumors and 
micro-metastasis is problematic in CC2. The host immune response evasion by 
Human Papilloma Virus (HPV) associated CC has been reviewed elsewhere3. 
Cytokines such as Interleukin (IL) 10, IL13 and transforming growth factor β 
(TGFβ) are known to be involved in evasion of CC from the immune system 
response3,4. Tumor-associated inflammation and the inflammatory components 
present in the tumor microenvironment are also recognized as having a role in 
tumor development5. This is mediated in part through the supply of bioactive 
molecules to the tumor microenvironment. These include growth factors, survival 
factors, pro-angiogenic factors, extracellular matrix-modifying enzymes, as well 
as the inductive signals that lead to activation of epithelial-mesenchymal 
transition (EMT)2. This phenomenon is orchestrated by a plethora of cytokines 
and chemokines. In CC, cytokines such as IL6, -86 and -177 as well as 
chemokines such as CCL28 are known to exert these pro-inflammatory effects. 
Expression of these molecules in the tumor microenvironment is tightly regulated 
by transcription factors. 
 
Krüppel like factors (KLF’s) are a family of transcription factors that participate in 
various aspects of cellular growth, proliferation and differentiation9. This family is 
characterized by three C2H2-type zinc finger domains that bind to either CACCC 
elements or GC boxes in the promoter of target genes to regulate transcriptional 
activity and gene expression9. Recently, we have reported the expression of 
several members of the KLF family in CC including KLF1010. KLF10 can function 
as a trans-activator or –repressor11. It has been previously reported that KLF10 is 
expressed in several tissues and various cell types that include smooth muscle, 
heart, glial cells, fibroblasts, myeloid cells,12 and lymphoid cells11. Gene-targeting 
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studies have implicated important roles for KLFs in immune and hematopoietic 
cell biology. For example, in CD4+CD25- cells, KLF10 is known to play an 
important role in T-cell activation and differentiation as well as Treg suppressor 
functions through regulation of TGFβ11. It has been reported that KLF10 can also 
directly regulate the pro-inflammatory cytokine IL12p4013.  
 
In addition to the above-mentioned functions of KLF10 in multiple cell and tissue 
types, no one has implicated a role for KLF10 in CC. In this report we have 
analyzed the molecular alterations of KLF10 in CC and have identified potential 
KLF10 target genes by means of DNA copy number variation (CNV) and mRNA 
transcription using microarrays, in silico analyses and putative transcriptional 
regulatory networks using gene knock-down approaches in vitro and in vivo. 
  
Results 
Genome copy number alteration in cervical cancer, 8q22.3 and 19q13.31 
gain 
To detect new genes associated with immune response in cervical cancer, our 
first approach was to identify cytogenetic regions harboring DNA gains. The 
results of our studies revealed that there were representative regions such as 1q, 
particularly 1q32.1 where the IL10 and IL24 genes are encoded, with over 
representation in ~23% of the CC samples. As expected, chromosome 3 showed 
mostly gain of DNA material. The most altered regions in the chromosome were 
at 3q26 and 3q21 where ~60% of the CC samples showed gains in DNA 
material. Recently, we reported that a tumor suppressor gene in CC, CRBP1 was 
located in the same region14.  
Interestingly, chromosome 8q22.3 where KLF10 gene is localized was also 
gained in ~20% (22/115), lost in ~7% (8/115) and unchanged in the remaining 
73% (85/115) of the CC samples.  
Since immune related genes play an important role in CC, it was of interest to 
look for their alterations in CC. These studies revealed that the 19q13.31 region 
was gained. The Pregnancy-Specific Beta-1 Glycoproteins (PSG), PSG2 gene 
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was gained in ~20% (22/115), lost in ~7% (8/115) and unchanged in 73% 
(85/115). The PSG5 gene was gained in ~20% (23/115), lost in ~6% (5/115) and 
unchanged in 76% (87/115) of the CC samples (Figure 1). Validations of these 
CNV results are required. 
 
KLF and immune response genes exhibit altered expression in CC 
Once the candidate genes were spotted by DNA gain in copy number, our 
second approach was to examine their mRNA expression levels using microarray 
analysis. For this purpose, we compared the transcriptome of normal cervix and 
cervical cancer tissues, by in silico analysis of publically available microarray 
libraries.  
Kruppel like factors 5 and 6 were among other genes that exhibited alterations in 
these analyses. These two genes were previously described to be up-regulated 
in CC by our group10.  
In spite of DNA amplification, KLF10 mRNA expression levels did not differ 
between normal and CC tissues (Figure 2), and there where no significant 
clinico-pathological correlations with KLF10 (Table 1).  
Interestingly, genes from the PSG family exhibited increased expression in CC 
(Figure 2). Multiple interleukins and chemokines including IL17, CXCL8, CXCL1, 
CXCL10 and CCL20 were up-regulated in CC samples compared to normal 
tissue (Figure 2). We also observed homogeneous expression patterns for KLF3, 
-7, -8, -11 and -15. However, only KLF10 and KLF15 consistently exhibited copy 
number gains across these samples. Of these two genes, only KLF10 is known 
to play an important role in immune regulation.   
 
Up-regulation of PSG2, PSG5 and IL25 genes in cervical cancer tissue 
biopsies 
The transcripts exhibiting altered expression in the in silico CC microarray 
analyses were further evaluated in the cervical cancer biopsies collected (20 CC 
and 3 normal cervix samples). We decided to validate the PSG2 and PSG5 
genes, because they were found to be consistently gained in copy number and 
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alternatively expressed in CC. Simultaneously, we also evaluated IL25 (IL17E), 
because several IL17 family members were up-regulated in CC samples and 
also participate in immune regulation. RT-qPCR analyses revealed increased 
expression of PSG2 and PSG5 by 1.76 and 3.97 fold respectively in CC 
samples, compared to normal tissues. At the same time, a 2.25 fold up-regulation 
of IL25 was observed in CC samples (Figure 2). These genes could represent 
attractive targets for immune based therapy. 
  
KLF10 knock down (KD) in SiHa cervical carcinoma cells down-regulates 
the PSG2 and PSG5 genes 
Given our findings of DNA copy number gains and the increased expression of 
the PSG genes and IL25, we next assessed the proximal promoter regions of the 
PSG2, PSG5 and IL25 genes for KLF10 binding sites. Interestingly, the proximal 
core promoter regions of the PSG2, PSG5 and IL25 genes contained at least two 
putative KLF binding sequences (Figure 3). To explore this further, we knocked 
down KLF10 in the SiHa cervical cancer cell line and perform microarray 
analyses.  
The SiHa cell line was chosen as an experimental model for KLF10 knock down 
because this cell line was established from a cervical squamous cell carcinoma 
that contains HPV16 sequences, most of CC cases have similar parameters. 
Once the validation of at least 70% down regulation of KLF10 protein expression 
was achieved (Figure 3), we carried out microarray analysis to identify altered 
genes whose expression levels were altered due to suppression of KLF10 
expression.  
Genes previously described as transcriptionally regulated by KLF10 such as 
fibroblast growth factor receptor (FGFR), epidermal growth factor receptor 
(EGFR), TGFβ receptor II, and runt-related transcription factor (RUNX) among 
others showed down-regulation in the KLF10 knocked down cells. 
Supplementary Table 1 and 2 shows the list of genes up- and down-regulated. 
Pathway analysis of the microarray data using genes whose expression was 
significantly decreased by at least 1.5 fold indicated that KLF10 participates in 
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several processes including the melanoma pathway and metabolism of 
xenobiotics by cytochrome P450 among others.  
DAVID and WebGESTALT based gene pathway analysis showed that the most 
altered events were associated with cytokines. The down-regulated cytokines 
detected in the microarray analysis included IL6, IL17A, IL25 and the 
chemokines CXCL1, -11 -13, CCL3, -11, -13, -16 among others (Figure 3, Table 
2). We also observed suppression of Arachidonate Lipoxygenase (ALOX) 
ALOXE3 and ALOX15, which are bioactive lipid metabolizing enzymes known to 
be associated with immune modulation.  
As expected, down-regulation of PSG2 and -5 were observed following 
suppression of KLF10 (Figure 3). The genes down-regulated were not the only 
ones affected in relation to immune system response, the up-regulation of 
several genes involved in immune-related functions were also observed, that 
include IL7, IL17C, and IL32. Chemokine CCL14 and a number of cytokines and 
chemokines receptors were also up-regulated. 
 
Down-regulation of PSG and Interleukin mRNA in KLF10 KD cells 
Altered expression of PSG2, PSG5 and IL25 following KLF10 knock down were 
selected for further validation because of their correlation with DNA gain in copy 
number and microarray expression patterns in CC, and their previous association 
with immune system response. Since IL6 is known to be up-regulated in CC5, we 
used this as a control to validate the microarray results. Of the transcripts 
analyzed, PSG2 was the most differentially expressed gene, both in the 
microarray data (-2.87) as well as in the RT-qPCR analysis with a down 
regulation of 89% in the KLF10 siRNA treated cells compared to control cells, 
IL25 was down-regulated by 52%, PSG5 by 43% and IL6 by 38% following 
knockdown of KLF10 (Figure 3). 
 
Microarray results of cervical tissues of KLF10 knock out (KO) mice  
Genes previously known as direct transcriptional targets of KLF10 including 
FGFR and RUNX exhibited down regulation in KO mouse cervical tissue, results 
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that were similar to our KLF10 knocked down CC cell line (Supplementary Table 
3 and 4).  
DAVID and WebGESTALT KEGG-based analyses of the down-regulated genes 
revealed that KLF10 participates in processes such as neuroactive ligand-
receptor interaction, cancer related pathways as well as metabolism of 
xenobiotics by cytochrome P450, JAK-STAT signaling, cell adhesion molecules 
(CAM’s), cytokine-cytokine receptor interaction and the chemokine signaling 
pathways (Table 3). 
Interestingly, immune response genes such as PSG17, -21, -23, IL11, interleukin 
1 receptor-like 1 (IL1RL1), IL1RAP, chemokines CCR8, CCL28 and XCL1 
(Figure 3) were also down-regulated in KLF10 KO cervical tissues. Additionally, 
ALOX15, which was recently described to participate in the immune response in 
cancer, was also down regulated in KLF10 mice. Up-regulation of IL21, IL12B 
and cytokine and chemokine receptors as well as IL3RA, IL9R and CCR4 were 
observed. These results are in concordance with the results obtained in our cell 
line studies. 
 
Validation of PSG mRNA results in KLF10 KO mice  
The PSG family members were chosen for RT-qPCR validation, as they are 
relatively novel molecules involved in cancer and pregnancy immune system 
regulation. As shown in Figure 3, we observed that PSG17 was down-regulated 
18%, PSG21 90% and PSG23 92% in KLF10 KO mouse cervical tissues 
compared to KLF10 WT controls (Figure 3). 
 
KLF10 associates with PSG gene promoters 
Given our results indicating decreased expression of PSG2 and -5 in SiHa 
cancer cells and cervical tissues following loss of KLF10 expression, and in light 
of the in silico analyses indicating putative KLF10 binding sites located in the 
promoter regions of these genes, we sought to determine if KLF10 indeed binds 
to these sites. Chromatin immunoprecipitations assays (ChIP) confirmed KLF10 
binding to the PSG2 and PSG5 promoter regions. These results are consistent 
 9
with our gene expression studies and provide further evidence that PSG2 and 
PSG5 are direct KLF10 target genes in the cervix (Figure 3). 
 
Discussion 
Genomic instability is manifested by gains and losses of chromosomal regions in 
cancer. Importantly, the recurrence of specific aberrations (both amplifications 
and deletions) at particular sites in the genome indicates that such sites are likely 
to harbor genes whose alteration favors neoplastic progression2. Along with DNA 
alterations, transcriptomic analysis and particular mRNA expression profiles 
could indicate which molecular pathways are altered and contribute to disease 
development and progression. In the present study, we have identified novel 
molecular markers that are likely to play important roles in CC and its immune 
regulation. Although many genes were identified, KLF10 was a transcription 
factor that exhibited copy number amplification and which exhibited high 
expression levels in cervical cancer biopsies10. This gene is known to play an 
important role in immune response and TGFβ signaling pathway10. Copy number 
amplification of this gene has also been reported in lung cancer15. 
Low-Grade squamous intraepithelial lesions exhibit slightly altered patterns of 
differentiation and are frequently cleared by the immune system in less than a 
year, however, some of these lesions can persist and progress to CC3.   
Immune system response, both pro- and anti- inflammatory processes, has 
recently been recognized as part of the “hallmarks of cancer” and plays a pivotal 
role in the development and progression of transformed cells2. It has been 
reported that there is an imbalance in the Th1/Th2/Th17 immune responses that 
are associated with differential expression of anti- and pro- inflammatory 
cytokines in CC16,17.  
By a broad definition, inflammation involves tissue-remodeling events that are 
associated with alterations in epithelial, vascular and immune cell functions18. 
Specific molecular pathways involving a host of transcription factors, cytokines, 
chemokines, growth factors and lipid mediators orchestrate these events. KLF 
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family members have been implicated in the function and differentiation of 
immune cells19. 
The up-regulation of IL6 in CC has been reported20 to promote the expression of 
vascular endothelial growth factor (VEGF) via the STAT3 pathway, and therefore 
possibly mediates angiogenesis21 and autocrine growth factor signaling22. In light 
of immune cell skewing, IL6 has been shown to promote Th2 differentiation by 
induction of IL12, to inhibit Th1 differentiation by suppression of IFNγ, and 
participates in B cell and macrophages differentiation23 and probably recruitment 
of Th17 cells24.    
IL25 (IL17E) belongs to the IL17 family and has been implicated in the 
expression of NF-κβ, activation of MAPK, as well as promotion of eosinophilic 
infiltration, mucus production and epithelial cell hyperplasia25. It is also involved 
in Th2 and Th9 differentiation26. To our knowledge this is the first report 
indicating IL25 up-regulation in CC, although its role in this disease is not yet fully 
understood. IL25 was not the only member of the IL17 family affected by down-
regulation of KLF10 as IL17A also exhibited decreased expression at the mRNA 
level in the present study. This gene has been shown to be over expressed in CC 
and plays a critical role in migration by induction of matrix metalloproteinase 2 
and -9 trough p38/NF-κβ pathway27 and regulates angiogenesis by induction of 
VEGF28.  
On the other hand, Pregnancy-Specific Beta-1 Glycoproteins comprise a family 
of 10 genes (PSG1-9, and -11) and one pseudogene (PSG10) clustered in the 
19q13.31 cytogenetic region. They are members of the carcinoembryonic antigen 
family29. Our CNV results show a gain in copy number of the 19q13.31 
cytogenetic region, were the PSG gene cluster is encoded. Here we report the 
up-regulation of two members, PSG2 and PSG5, and to our knowledge this is the 
first report showing up regulation of PSG mRNA molecules in CC. Members of 
the PSG family have been shown to be up-regulated in breast and gastric 
cancers 30,31. The members of this family have also been implicated in 
angiogenesis as well as tubulogenesis by two possible mechanisms, one by the 
regulation of TGFβ and the other by interaction with glycosaminoglycans29. The 
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PSG family members are also involved in the differentiation of Th1, Th2, Th17 
and Treg cells by increasing the expression of cytokines such as IL6, -10, -17 
and TGFβ32,33.  
Through the use of in silico analyses, we have demonstrated that IL6, IL25 and 
PSG genes are potential targets for KLF10 since they possess KLF binding sites 
in their proximal promoters. This possibility was confirmed by ChIP assay 
demonstrating recruitment of KLF10 to these putative binding sites. There is 
evidence that KLF10 acts as a transcriptional regulator of cytokines and 
chemokines including IL12p40, TGFβ11 and possibly IL613 CCR7 as well as the 
receptor CXCR434. There is also clear evidence that other members of the KLF 
family can regulate the transcription of PSG genes29. It has been shown that CC 
derived cells exhibit deregulation of IL6, IL17A and IL17E which subsequently 
influencing leukocytosis35.  All of these CC derived cell lines also express KLF10, 
as evidenced from our findings. Similarly, there are reports demonstrating that 
KLF10-/- mice have higher expression of cytokines that influence the Th1 and Th2 
differentiation profiles9. Our results support the possibility that KLF10 plays an 
important role in regulating essential genes such as PSG2 and -5 in CC and also 
plays a critical role in immune modulation within the cervix. Given that KLF10-
specific small molecule inhibitors have been developed and are known to elicit 
potent effects in T cells36, such drugs could represent a novel treatment for CC. 
 
Conclusions  
Here, we demonstrate that KLF10 plays important roles in the transcriptional 
regulation of genes involved in the immune system response including IL6, IL25 
and members of the PSG family. Regulation of these genes is important with 
regard to the immunoediting process in cervical tissue and likely contributes to 
CC development and progression. The gain in DNA copy number for the 8q22.3 
and 19q13.31 cytogenetic regions represent potential DNA molecular markers in 
CC. The increased expression of IL25, PSG2 and PSG5 could also serve as 
molecular markers and potential drug targets for immune-based therapies in CC, 
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and may also play important roles in the balance of the immune system response 
in CC.  
 
Materials and Methods  
CNV in silico analysis, data mining and analysis  
For copy number variation analysis, a total of 115 cancer libraries and 32 control 
libraries corresponding to GSE10092 and GSE52904 were downloaded and 
quality control checked prior to analysis. Partek v6.6 (Partek Incorporated, Saint 
Louis, MO, USA) were used with stringent parameters set as follows: each 
segment must contain a minimum of 10 consecutive filtered probe sets, a p-value 
threshold of 0.001 when compared to the neighboring adjacent regions and a 
signal-to-noise threshold of 0.5. The cut-off value for the gain was set at above 
2.3, while loss was set at below 1.7. CNV was called for the gains or losses that 
occurred in at least 10% of the total samples. The 22 somatic chromosomes and 
the X chromosome were analyzed. Hierarchical clustering was performed using 
the following parameters: sample dissimilarity: Euclidian and cluster method: 
average linking.   
In silico analysis of the cervical cancer transcriptome 
A total of 8 normal (N) and 57 cervical cancer (CC) experiments were 
downloaded and analyzed. The data used for these analyses were downloaded 
from European Bioinformatics Institute (EMBL-EBL) and GEO. These data 
correspond to GSE7307, GSE5787, GSE3526 and 1 Gene Expression Atlas 
(GSE2109) corresponding to Affymetrix Human Gene Chip U133 platform. 
Quality control checks were performed on all transcriptomic libraries downloaded, 
prior to inclusion in the analysis. 
Data sets were analyzed by means of CEL files with the Expression Console, 
Partek Genomics Suite 6.6v software (Partek Incorporated, Saint Louis, MO, 
USA) and Transcriptome Analysis Console (Affymetrix, Santa Clara, CA, USA). 
Pearson and Spearman correlation was performed and probe sets were 
summarized by means of Median Polish and normalized by quantiles with no 
probe sets excluded from analysis. Background noise correction was achieved 
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by means of Robust Multi-chip Average (RMA) and data were log2- transformed. 
Data grouping and categorization was achieved by principal component analysis 
(PCA). Differentially expressed genes were determined by means of ANOVA. 
Genes were considered altered with +1.5 or -1.5 fold change, p≤0.05 and 
FDR>0.05 parameters. 
 
Cervical tissue collection 
For confirmation of the in silico findings, we collected three histologically normal 
tissues and twenty carcinomas. Patients were recruited with signed informed 
consent and ethical approval from the Comisión Nacional de Ética e 
Investigación Científica del Instituto Mexicano del Seguro Social in accordance 
with the Helsinki declaration. These same cervical tissues have been previously 
described10. 
 
KLF10 knock out and wild type mice 
Eight weeks old female KLF10-/- knockout (KO) and KLF10+/+ wild-type (WT) 
mice were used for isolation of the cervical tissues that were used in the 
microarray experiments. The KLF10 KO mice used in this study were generated 
as described previously37. This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Mayo Clinic 
Institutional Animal Care and Use Committee. 
 
Cell culture and siRNA treatment 
All reagents used for the cell culture and siRNA transfection were purchased 
from Life Technologies (Foster City, USA) unless otherwise stated. 
The SiHa cell line was cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
at 37°C in 5% CO2 in 12 well plates. Transient transfection was performed using 
KLF10-specific Silencer Select siRNA: s14129 and s14128, and Lipofectamine 
RNAiMAX reagent was used for transfection. Briefly, approximately 90’000 SiHa 
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cells per well were seeded and cultured overnight. Seventy nM siRNA was 
diluted in Opti-MEM media generating solution 1, Lipofectamine RNAiMAX was 
diluted in Opti-MEM media generating solution 2. Solution 1 and 2 were mixed at 
equal volumes and incubated at room temperature for 20 min, following the 
manufacturer’s protocol, and the mixture was added to SiHa cells in a total 
volume of 500 μl. As a negative control, a scrambled siRNA (AM4611) was 
transfected with the same conditions as the KLF10 siRNA mentioned above. A 
GFP expression construct was used as a positive control. For comparison 
purposes, SiHa cell cultured in the absence of any treatment were also 
examined. Six hours following transfection, 500 μl of DMEM supplemented media 
was added to the cell culture. All treatments were performed in triplicate a 
minimum of three independent times. Forty-eight hours post transfection; RNA 
was isolated, pooled and used for microarray experiments. 
 
Hybridization and analysis of microarray data  
Printing of arrays. Human 70-mer oligo library from OPERON Oligo Sets 
(http://omad.operon.com/) was resuspended to 40M in Micro Spotting solution 
(Telechem International Inc.). SuperAmine coated slides, 25x75 mm (TeleChem 
International INC) were printed in single copy, and fixed at 80°C for 4 hours. For 
pre-hybridization, the slides were re-hydrated with water vapor at 60°C, and fixed 
with two cycles of UV light (1200J). After boiling for two minutes at 92°C, slides 
were washed with 95% ethanol for one minute and prehybridzed in 5X SSC, 
0.1% SDS and 1% BSA for one hour at 42°C. The slides were washed and dried 
prior to hybridization. 
Probe preparation and hybridization to arrays. RNA integrity was analyzed 
both by agarose gel electrophoresis and by a Bioanalyzer 2100 and only 
samples with RNA Integrity Numbers (RIN) greater than 8 were used in these 
assays. 10 μg of total RNA were used for cDNA synthesis incorporating dUTP-
Alexa555 or dUTP-Alexa647 employing the CyScribe First-Strand cDNA labelling 
kit (Amersham). Incorporation of fluorophore was analyzed by absorbance at 555 
nm for Cy3 and 655 nm for Cy5. Equal quantities of labeled cDNA were 
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hybridized using hybridization solution HybIT2 (TeleChem International INC). The 
arrays were incubated for 14 h at 42°C, and then washed tree times with 1X 
SCC, 0.05 % SDS at room temperature. Cy3 labeling was used for control SiHa 
control cells and WT mouse tissue while Cy5 labeling was used for KLF10 
siRNA-treated cells and KO mouse tissue.  
Data acquisition and analysis of array images. Acquisition and quantification 
of array images was performed in ScanArray 4000 with its accompanying 
software ScanArray 4000 from Packard BioChips. All images were captured 
using 65% PMT gain, 70 to 75% laser power and 10µm resolution at 50% scan 
rate. For each spot the Cy3 and Cy5 density mean value and the Cy3 and Cy5 
background mean value were calculated with software ArrayPro Analyzer from 
Media Cibernetics.  
Data analysis. Microarray data analysis was performed with free software 
genArise, developed in the Computing Unit of Cellular Physiology Institute of 
UNAM (http://www.ifc.unam.mx/genarise/). GenArise carry out a number of 
transformations: background correction, Lowess normalization, intensity filter, 
replicates analysis and selecting differentially expressed genes. The goal of 
genArise is to identify which of the genes show good evidence of being 
differentially expressed. The software identifies differential expressed genes by 
calculating an intensity-dependent z-score. Using a sliding window algorithm to 
calculate the mean and standard deviation within a window surrounding each 
data point, and define a z-score where z measures the number of standard 
deviations a data point is from the mean. 
1).- zi = (Ri – mean(R)) / sd(R) 
Where zi is the z-score for each element, Ri is the log-ratio for each element, and 
sd(R) is the standard deviation of the log-ratio. With this criterion, the elements 
with a z-score > 1.5 standard deviations would be the significantly differentially 
expressed genes.  
Furthermore, WebGESTALT (http://bioinfo.vanderbilt.edu/webgestalt/) and 
DAVID (http://david.abcc.ncifcrf.gov) were used for identifying and understanding 
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the biological pathway and processes that are significantly altered based on the 
gene expression profiles. These analyses were conducted using KLF10 target 
genes that were significantly down regulated in KLF10 siRNA treated cells or 
KLF10 KO tissues. 
 
RNA extraction, reverse transcription reaction and RT-qPCR  
RNA was extracted from SiHa siRNA-treated and control cells, mouse KO and 
WT cervical tissue and the cervical cancer biopsies from patients using the 
RNAeasy Mini Kit (Qiagen Inc, CA, USA) according to manufacturer’s 
instructions. RNA was quantified using a Nanodrop-ND-1000 (Thermo Scientific, 
DE, USA) and RNA integrity was evaluated on 1.5% agarose gel and by a 
Bioanalyzer 2100. After purification, 1 μg of total RNA was reverse transcribed in 
a 20 μl final volume reaction with the High capacity RNA-to-cDNA Kit (Applied 
Biosystems, Foster City, USA), 11 μl of Mix were added, and the reaction mixture 
was incubated at 37°C for 60 min., and 95°C for 5 min., and held at 4°C 
indefinitely according to manufacturer protocols. For RT-qPCR of human PSG2, 
PSG5, IL6, Il25 and mouse PSG17, PSG21 and PSG23 all reagents were 
purchased from Applied Biosystems (Foster City, USA), and conditions were as 
follows: 11 μl of Taqman Gene Expression Master Mix, 1 μl of each Taqman 
probe, 500 ng of cDNA in a 20 μl final volume, according to manufacturers 
recommendation. RLPO and GAPDH for human and mouse respectively, were 
used as internal controls and all reactions were conducted in triplicate in the Step 
one thermal cycler (Applied Biosystems). 2-∆∆Ct was used to calculate relative 
expression levels. Probe Id’s are listed in Supplementary Material and Methods 
Table 1. 
 
Chromatin immunoprecipitation for KLF10 binding sites in PSG promoters 
Chromatin immunoprecipitations (ChIP) were performed using the EZ-ChIP kit 
(#17-371 Millipore, Darmstadt, Germany) according to the manufacturers 
instructions. Briefly, 70% confluent SiHa cells were fixed with 1% formaldehyde 
for 10 min at room temperature and quenched with 10x glycine for 5 min. After 
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quenching, cells were scraped in 1x PBS containing Protease Inhibitor Cocktail 
II, pelleted and the supernatant was discarded. Cell pellets were re-suspended in 
SDS Lysis Buffer containing Protease Inhibitor Cocktail II. Cells were sonicated 
on ice using Sonics Vibracell VCX130 (Sonics, CT, USA). After sonication cell 
debris was eliminated by centrifugation at 12 000 g for 10 min at 4°C. After this 
step, 900 μl of Dilution Buffer containing Protease Inhibitor Cocktail II was added 
to each 100 μl of sheared crosslinked chromatin. Pre-clearing process was 
carried out by incubating with 60 μl of the Proteing G Agarose beads for 1 h at 
4°C. The Protein G Agarose beads were collected by centrifugation at 4 000 g for 
1 min at 4°C. and10 μl was collected as the Input loading control. 
Immunoprecipitation was carried out using antibodies against RNA Pol II 
(positive control), mouse IgG (negative control), both provided by the EZ-ChIP kit 
manufacturer. KLF10 specific antibodies (GTX108661; Genetex, CA, USA) and 
992 (kindly donated by Drs. Subramaniam and Hawse, Mayo Clinic, USA) were 
also used. Immunoprecipitations were carried out via overnight incubation at 4°C 
with primary antibodies. Following incubation, 60 μl of Protein G Agarose beads 
was added and incubated for 1 hr at 4°C, and Antibody-Antigen-DNA was 
collected by centrifugation at 4 000 g for 1 min at 4°C. Beads were washed by 
suspending them and incubating them for 5 min at 4°C in Low Salt Immune 
Complex Wash Buffer one time, High Salt Immune Complex Wash Buffer one 
time, LiCl Immune Complex Wash Buffer one time and TE Buffer two times. 
Complexes were eluted two times in 100 μl of elution buffer (10 μl 20% SDS, 20 
μl de 1M NaHCO3 and 170 μl of water) and complex were suspended and 
incubated for 15 min at room temperature followed by centrifugation at 4 000 g 
for 1 min at 4°C. Supernatant was collected and transferred to a new tube, 
resulting in a final elution volume of 200 μl. To reverse DNA-Protein crosslinks, 
5M of NaCl was added and samples were incubated overnight at 65°C. Followed 
by addition of 1 μl of RNAse A and incubation at 37°C for 30 min, to deplete al 
RNA species. For DNA extraction, 4 μl of 0.5M EDTA, 8 μl of 1M Tris-HCl and 1 
μl of Proteinase K were added, and incubated for 4 hrs at 45°C. DNA purification 
was performed using columns and reagents provided by the kit. Binding Buffer A, 
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1ml for every 200 μl of elution buffer, was added, and 600 μl transferred to the 
column, centrifuged 12 000 g for 30 sec, this step repeated two times, until the 
1.2 ml were passed through the column. Column was washed with 500 μl of 
Washing Buffer B and centrifuged 12 000 g for 30 sec. Centrifugation at 12 000 g 
for 30 sec was repeated to eliminate the excess of buffers in the column. DNA 
was eluted in 50 μl of Elution Buffer C by centrifugation at 12 000 g for 30 sec. 
To evaluate candidate gene-promoters PCR was conducted as follows; 12.5 μl of 
GoTaq® Green Master Mix (Promega, WI, USA), 5 μl of ChIP-DNA template, and 
20 pmol of each primer, in a 25 μl total volume reaction, with the following 
program: 30 seconds at 95°C, 30 seconds at 59°C and 30 seconds at 72°C for 
32 cycles.  
The GAPDH promoter was analyzed in the ChIP assays as a positive control 
(RNA Pol II Ab), Pregnancy-Specific Beta-1 Glycoproteins 2 and 5 gene 
promoters were evaluated in KLF10 ChIP and IgG ChIP (Negative control) 
samples. Sequences of corresponding primers are listed in Supplementary 
Material and Methods Table 1. 
 
Statistical analysis  
Clinical and pathological relation analysis was performed by means of the 
Student’s t-test for the gene expression studies and for clinical and pathological 
parameters that were normally distributed in the data sets.  For non-normally 
distributed parameters, the Mann-Whitney U test was utilized. All p-values 
represent two-tailed tests and were considered significant at 0.05. Statistical 
analysis was performed using SPSS v15 statistical software.  
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Tables 
Table 1.- Clinical-pathological correlations with KLF10 expression 
* Statistical significance  
 
 
 
Clinical Variables Average±SD KLF10 
(p) 
PSG2 
(p) 
PSG5 
(p) 
Il25 
(p) 
Age 51.4±15.18 0.53 0.03* 0.196 0.708 
≥50 12     
<50 8     
Pregnancies Number 4.05±2.76 0.12 0.781 0.027* 0.403 
≥3 13     
<3 7     
Pregnancy natural deliveries 3.65±2.94 0.99 0.525 0.60 0.651 
≥3 11     
<3 9     
Sexual activity age onset  18.88±5.48 0.41 0.20 0.315 1.0 
≥18 13     
<18 7     
First menstruation 13.6±1.75 0.66 0.609 0.159 0.286 
≥12 17     
<12 3     
Sexual partners number 1.7±1.21 0.19 0.309 0.384 0.166 
≥2 8     
<2 12     
Tobacco consumption   0.34 0.740 0.085 0.211 
Positive 12     
Negative 8     
Alcohol consumption  0.34 0.238 0.018* 0.101 
Positive 15     
Negative 5     
Contraceptives  0.79 0.38 0.056 0.525 
Positive 14     
Negative 6     
Diagnostic  0.77 0.026* 0.011* 0.008*
CC 20     
Non-CC 3     
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Table 2.- KEGG-based pathway analysis results from down-regulated genes in 
KLF10-siRNA treated SiHa cell line obtained from DAVID  
 
 
 
 
 
 
 
 
 
 
 
Category Term Count Genes 
KEGG_PATHWAY hsa05218:Melanoma 13 EGFR, BRAF, FGF16, MITF, IGF1, CDH1, FGF12, 
RB1, PDGFC, FGF1, FGF2, PIK3R1, FGF4 
KEGG_PATHWAY hsa04810:Regulation 
of actin cytoskeleton 
29 SSH1, APC2, WASF1, FGF16, IQGAP3, FGF12, 
ITGB3, DOCK1, TIAM1, ARPC2, ITGAV, ITGB6, 
PDGFC, FGF1, FGF2, PIK3R1, FGF4, APC, EGFR, 
BRAF, IGF2, PPP1CB, CHRM5, CFL2, CFL1, ITGA7, 
CYFIP1, CRK, MYH10 
KEGG_PATHWAY hsa00983:Drug 
metabolism 
9 CYP3A5, NAT1, NAT2, CYP2A7, UGT2A3, HPRT1, 
UGT2B28, IMPDH1, UGT2B7 
KEGG_PATHWAY hsa04060:Cytokine-
cytokine receptor 
interaction 
32 CXCL1, IFNA21, CNTFR, CXCL11, TNFRSF1A, 
IL17A, IL1RAP, TPO, CSF2RB, PDGFC, IFNK, 
IFNA8, PRL, RTEL1, IFNGR1, EGFR, IL6, IL2RA, 
IL29, TGFBR2, IL25, LIFR, TNFRSF17, EDA2R, 
CCL4L1, CCL16, CCL11, IFNAR2, CCL13, CXCL13, 
NGFR, IFNA17 
KEGG_PATHWAY hsa00980:Metabolism 
of xenobiotics by 
cytochrome P450 
10 CYP3A5, GSTM3, GSTM4, CYP2F1, ADH1B, 
GSTO1, UGT2A3, UGT2B28, UGT2B7, ALDH3A1 
KEGG_PATHWAY hsa04910:Insulin 
signaling pathway 
18 BRAF, PHKB, PRKCI, PRKAB1, PDE3B, IGF2, 
RPS6, PPP1CB, IRS1, GCK, SLC2A4, PRKAR1B, 
PKLR, GYS1, SHC1, CRK, CALM2, PIK3R1 
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Table 3.- KEGG-based pathway analysis results from down-regulated genes in 
KLF10-/- (KO) mouse cervical tissue obtained from DAVID  
 
Category 
 
Term 
 
Count 
 
Genes 
 
KEGG_PATHWAY 
 
mmu03030:DNA 
replication 
 
8 
 
PRIM1, RFC3, RFC4, LIG1, POLE, POLA1, 
RNASEH1, RNASEH2B 
 
KEGG_PATHWAY 
 
mmu04630:Jak-
STAT signaling 
pathway 
 
18 
 
GRB2, CSF2RB2, CTF1, PIK3CD, SOCS4, 
SOCS5, IL7R, CISH, IL11, IL6RA, LIF, 
SPRY1, ILTIFB, PIAS3, SOS1, SPRED2, 
PIK3CA, PIAS1 
 
KEGG_PATHWAY 
 
mmu04080:Neu
roactive ligand-
receptor 
interaction 
 
26 
 
F2RL2, AVPR2, C3AR1, THRB, TRHR, 
BDKRB1, FPR3, NR3C1, EDNRA, HCRTR1, 
HRH3, ADRA2A, TAAR1, CALCRL, HTR1D, 
GABRG2, GABRG3, CCKBR, PTH2R, 
TRHR2, NPBWR1, GABRR1, CHRM2, 
P2RY14, MTNR1B, MTNR1A 
 
KEGG_PATHWAY 
 
mmu04514:Cell 
adhesion 
molecules 
(CAMs) 
 
17 
 
CLDN16, SELP, PTPRC, ICOSL, H2-D1, 
CDH1, NCAM1, SIGLEC1, ITGB2L, CD80, 
ITGAV, PVRL2, H2-AA, CNTN1, VCAN, 
4930468A15RIK, CD28 
 
KEGG_PATHWAY 
 
mmu05211:Ren
al cell 
carcinoma 
 
10 
 
CDC42, CUL2, GRB2, SOS1, PIK3CD, 
ARNT2, GAB1, TCEB2, PIK3CA, PAK1 
 
KEGG_PATHWAY 
 
mmu04722:Neu
rotrophin 
signaling 
pathway 
 
15 
 
GRB2, PIK3CD, NTRK3, MAGED1, CDC42, 
SOS1, MAP3K1, NTRK2, GAB1, PIK3CA, 
SORT1, NGFRAP1, SH2B2, MAPK7, 
CAMK2A 
 
KEGG_PATHWAY 
 
mmu04512:EC
M-receptor 
interaction 
 
10 
 
CD47, LAMA3, CD36, CD44, NPNT, ITGAV, 
COL3A1, AGRN, ITGB3, COL11A2 
 
KEGG_PATHWAY 
 
mmu04540:Gap 
junction 
 
10 
 
GJD2, ADCY7, GRB2, SOS1, TUBA4A, 
GUCY1B2, MAPK7, PRKACB, PRKG1, 
TUBA1B 
 
KEGG_PATHWAY 
 
mmu04520:Adh
erens junction 
9 
 
PTPRJ, FGFR1, CDC42, IGF1R, PVRL2, 
CTNND1, CDH1, WAS, SNAI1 
 27
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
KEGG_PATHWAY 
 
mmu00980:Met
abolism of 
xenobiotics by 
cytochrome 
P450 
 
8 
 
GSTM3, CYP3A16, CYP1A1, CYP2B19, 
GSTZ1, CYP2B10, CYP2C39, CYP3A44 
 
KEGG_PATHWAY 
 
mmu04060:Cyto
kine-cytokine 
receptor 
interaction 
 
19 
 
CSF2RB2, TNFRSF25, CTF1, IL7R, CCL28, 
IL11, TNFSF8, IL6RA, LIF, CCR8, 
TNFRSF11B, ILTIFB, INHBC, IL1RAP, 
TNFRSF18, XCL1, BMP7, XCR1, EDA 
 
KEGG_PATHWAY 
 
mmu04062:Che
mokine 
signaling 
pathway 
 
14 
 
ADCY7, GRB2, PIK3CD, CCL28, WAS, 
CCR8, CDC42, SOS1, IKBKG, PIK3CA, 
PAK1, PRKACB, XCL1, XCR1 
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Figure Legends 
Figure 1.- Chromosomal imbalances in CC. Panel A) hierarchical clustering 
indicating genomic DNA gains in red and losses in blue in the 22 somatic 
chromosomes and the X chromosome in 115 CC samples. Cervical cancer 
genomes show gains in 1p, 3q, 5p, 20, and 8q22.3 and 19q13.31 cytogenetic 
regions. Panel B) and Panel C) indicate the hierarchical clustering of the 8 and 
19 chromosomes across the CC samples analyzed. In panel A) white stripes in 
the acrocentric chromosomes 13, 14, 15, 21 and 22 corresponds to nucleolar 
organizer regions and stripes observed in chromosome 8 and 19 correspond to 
centromere on panel B and C. 
 
Figure 2.- Transcriptome analysis of cervical tissue. A) Heat map indicating 
differentially expressed genes between normal and CC samples as detected by  
in silico analysis of the array datasets. B) RT-qPCR validation of PSG2, PSG5 
and IL25 in cervical cancer samples collected by our laboratory. Black bars 
represent basal expression in normal cervical tissue while grey bars represent 
expression in cervical cancer. C) Hierarchical clustering indicating the expression 
levels of KLF family members in normal tissue and CC. D) RT-qPCR analysis 
demonstrating no significant differences in the expression levels of KLF10 
between normal (black bar) and CC (grey bar) tissue.   
 
Figure 3.- Relative expression analyses of IL25, PSG2 and PSG5 genes. 
Panel A1) Heatmap depicting expression levels of indicated immune system 
response genes that are down regulated  in SiHa cells following siRNA-mediated 
suppression of KLF10. Panel A2) Western blot depicting KLF10 protein levels in 
the knocked down cells compared to scrambled siRNA and untreated control 
cells. Panel A3) show RT-qPCR validation of the down-regulated genes in 
microarray data: IL6 with 38%, IL25 with 52% PSG5 with 43% and PSG2 with 
89% down regulation in KLF10 siRNA treated cells in comparison with the control 
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cells without any treatment. Panel B1) presents heatmap corresponding to 
immune system response related genes dowregulated in KLF10 KO mouse 
compared to KLF10 WT mouse. Panel B2) show RT-qPCR validation of PSG17 
down regulation of 18%, PSG21 90% and PSG23 92% down-regulation in KO 
mouse cervical tissue compared to WT mouse tissue. Black bars represent the 
control cells (KLF10ct) or the WT mouse (KLF10wt), while grey bars represent 
the KLF10 knock down cells (KLF10kd) and knock out mouse (KLF10ko) in each 
panel respectively. Panel C1)-C4) shows the in silico results for the analysis of 
promoter regions from IL6, IL25, PSG2 and PSG5 genes respectively, 
MatInspector module from Genomatix Software was used. Pink rectangles 
represent the putative region were KLF10 responsive sequence could be located. 
Panel D) show the KLF10-immunoprecipitated DNA. The first two lanes present 
PSG promoter region associated to KLF10. Whereas lanes three and four 
present GAPDH promoter in RNA Pol II immunoprecipitated DNA as positive 
control, and PSG5 promoter in IgG immunoprecipitated DNA as negative control. 
All ChIP lanes present Input DNA control. Agarose gel was cropped; all reactions 
were electrophoresed in the same gel.  
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